Abstract

Immunophotonics is developing inCVAX, an in situ autologous cancer vaccine, which combines thermal laser with immunotherapy for the treatment of metastatic cancers. Promising results have emerged in the preclinical and early clinical studies.

© 2015 OSA

PDF Article